profit from every $100 of sales.
$0$100
Jyong Biotech Ltd. Ordinary Shares
$1.68-3.45% today
-77.1% in 1 year
1-year low $1.461-year high $7.65
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Jyong Biotech Ltd. Ordinary Shares sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$4.67 million of profit last year.
SalesProfit
Jyong Biotech Ltd. Ordinary Shares vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Jyong Biotech Ltd. Ordinary Shares | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Jyong Biotech Ltd. Ordinary Shares's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -3 | -3 | -2 | -3 | |
| -6 | -4 | -2 | -2 | |
| -7 | -4 | -3 | -5 | |
| -0.09 | -0.06 | -0.04 | – | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 9 | 8 | 6 | 21 |
| Cash | 1 | 0 | 0 | 1 |
| Total debt | 14 | 17 | 18 | 19 |
| Total liabilities | 38 | 42 | 43 | 46 |
| -30 | -34 | -37 | -25 | |
| 76 | 76 | 76 | – | |
| – | – | – | – | |
| 22.4% | 12.9% | 8.3% | 18.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -3 | -3 | -4 | -3 | |
| 0 | – | – | – | |
| -3 | -3 | -4 | -3 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| – | – | – | – |
Valuation
- –
- –
- –
- -6.5×
- –
- –
- –
- -2.8%
- -2.4%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -2.5%
- 31.1%
- 4.2%
- -3.3%
- -8.1%
- –
Growth
- –
- –
- −39.3%
- –
- +1.5%
Financial health
- -42.0×
- -1.57
- 93.4%
- -2.0×
- 0.62
- 0.62
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 34%of 947
Bottom 21%of 872
Bottom 26%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
4No pass
Philip Fisher
48No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
38No pass
Terry Smith
39No pass
Questions about Jyong Biotech Ltd. Ordinary Shares
Is Jyong Biotech Ltd. Ordinary Shares a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Jyong Biotech Ltd. Ordinary Shares AI analysis
What does Jyong Biotech Ltd. Ordinary Shares do?
Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. It is in Biotechnology.
Does Jyong Biotech Ltd. Ordinary Shares pay a dividend?
No. Jyong Biotech Ltd. Ordinary Shares does not pay a dividend at the moment.
Is Jyong Biotech Ltd. Ordinary Shares stock halal?
Yes. Jyong Biotech Ltd. Ordinary Shares passes our halal screen: its business is permitted and its debt is 14% of its market value, under the 30% limit. How we check
How has Jyong Biotech Ltd. Ordinary Shares stock done over the past year?
Down 77.1% over the past twelve months, to $1.68. It traded between $1.46 and $7.65 and is 78.0% below its high.
Who are Jyong Biotech Ltd. Ordinary Shares's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Jyong Biotech Ltd. Ordinary Shares's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.